Vista Capital Partners Inc. acquired a new stake in Merck & Co., Inc. (NYSE:MRK – Free Report) in the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund acquired 3,740 shares of the company’s stock, valued at approximately $543,000.
A number of other hedge funds also recently added to or reduced their stakes in the business. Round Rock Advisors LLC raised its holdings in shares of Merck & Co., Inc. by 0.7% in the 2nd quarter. Round Rock Advisors LLC now owns 9,901 shares of the company’s stock valued at $1,272,000 after purchasing an additional 66 shares in the last quarter. Cypress Wealth Services LLC boosted its stake in shares of Merck & Co., Inc. by 0.5% during the third quarter. Cypress Wealth Services LLC now owns 13,807 shares of the company’s stock valued at $1,960,000 after purchasing an additional 69 shares in the last quarter. Code Waechter LLC boosted its stake in shares of Merck & Co., Inc. by 3.4% during the third quarter. Code Waechter LLC now owns 2,179 shares of the company’s stock valued at $317,000 after purchasing an additional 71 shares in the last quarter. Quest 10 Wealth Builders Inc. increased its holdings in Merck & Co., Inc. by 12.2% during the third quarter. Quest 10 Wealth Builders Inc. now owns 699 shares of the company’s stock valued at $102,000 after buying an additional 76 shares during the period. Finally, Cascade Financial Partners LLC increased its holdings in Merck & Co., Inc. by 0.5% during the second quarter. Cascade Financial Partners LLC now owns 14,746 shares of the company’s stock valued at $1,895,000 after buying an additional 80 shares during the period. 76.07% of the stock is owned by hedge funds and other institutional investors.
Analyst Ratings Changes
A number of research firms have weighed in on MRK. JPMorgan Chase & Co. upped their target price on Merck & Co., Inc. from $165.00 to $175.00 and gave the stock an “overweight” rating in a report on Friday, October 30th. TD Cowen lifted their price target on Merck & Co., Inc. from $137.00 to $155.00 and gave the company a “hold” rating in a report on Wednesday, September 23rd. UBS Group lifted their price target on Merck & Co., Inc. from $145.00 to $175.00 and gave the company a “buy” rating in a report on Thursday, August 20th. Jefferies Financial Group boosted their price target on Merck & Co., Inc. from $152.00 to $175.00 and gave the stock a “buy” rating in a research report on Thursday, August 20th. Finally, Argus began coverage on Merck & Co., Inc. in a research note on Tuesday, November 3rd. They set a “strong-buy” rating for the company. One equities research analyst has rated the stock with a Strong Buy rating, sixteen have issued a Buy rating, eleven have given a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat, Merck & Co., Inc. has an average rating of “Moderate Buy” and an average target price of $155.74.
Merck & Co., Inc. Stock Down 0.0%
Shares of Merck & Co., Inc. stock opened at $147.74 on Monday. The firm’s 50 day moving average price is $146.16 and its 200-day moving average price is $128.61. The company has a quick ratio of 1.14, a current ratio of 1.35 and a debt-to-equity ratio of 1.11. Merck & Co., Inc. has a 52-week low of $91.49 and a 52-week high of $156.92. The company has a market cap of $364.21 billion, a P/E ratio of 152.31, a PEG ratio of 6.77 and a beta of 0.13.
Merck & Co., Inc. (NYSE:MRK – Get Free Report) last posted its quarterly earnings data on Thursday, October 29th. The company reported $2.49 EPS for the quarter, topping the consensus estimate of $2.09 by $0.40. Merck & Co., Inc. had a net margin of 3.64% and a return on equity of 16.73%. The firm had revenue of $18.09 billion during the quarter, compared to analyst estimates of $17.33 billion. During the same quarter in the previous year, the business posted $2.58 EPS. Merck & Co., Inc.’s revenue was up 4.7% on a year-over-year basis. On average, sell-side analysts predict that Merck & Co., Inc. will post 2.82 EPS for the current fiscal year.
Merck & Co., Inc. Profile
Merck & Co., Inc. is a global pharmaceutical company that develops and markets prescription medicines, vaccines, biologic therapies and animal-health products. The company’s research and commercial activities span areas including oncology, infectious diseases, vaccines, cardiovascular disease and immunology. Its products include the cancer medicine Keytruda and the Gardasil vaccine. Founded in the United States in 1891, Merck & Co. became an independent company in 1917. It is headquartered in Rahway, New Jersey, and operates internationally.
Featured Articles
- Five stocks we like better than Merck & Co., Inc.
- 3 Large-Cap Stocks Are Outperforming the S&P 500 Without AI Hype
- Fossil Just Turned a Profit—Can Its Comeback Survive the Holidays?
- Beaming Up the Backlog: AeroVironment Lands $405M Laser Deal
- Intuitive Machines’ Business Is Taking Off—Will Its Stock Follow?
Receive News & Ratings for Merck & Co. Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Merck & Co. Inc. and related companies with MarketBeat.com's FREE daily email newsletter.
